Clinical trials: Neonatal Respiratory Distress
Respiratory Distress Syndrome, Newborn, Premature Birth
SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.
SURFAXIN® (lucinactant) treatment will be examined in very low birth weight infants to prevent development of chronic lung disease, commonly known as bronchopulmonary dysplasia (BPD), in premature infants who have required…
- Conditions
- Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
- Trial name
- NCT00215540
- Testing
- Lucinactant 175 mg/kg, Lucinactant 90 mg/kg
- Where
- United States
- Volunteers
- 136 people
- Sponsor
- Windtree Therapeutics
Acute Respiratory Distress Syndrome
Nitric Oxide Administration for Acute Respiratory Distress Syndrome
This research project is an open-label, randomized study for the use of Nitric Oxide in pediatric patients with acute respiratory distress syndrome (ARDS).
- Trial name
- NCT00240487
- Testing
- Nitric Oxide, No Intervention
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Children's Hospital of Philadelphia
Deglutition Disorders, Respiratory Distress Syndrome In Premature Infants
Effect of Nasal Continuous Positive Airway Pressure on The Pharyngeal Swallow in Neonates
Oral feeding of neonates while on nasal continuous positive airway pressure (NCPAP) is a common practice in many neonatal intensive care units (NICU) all over the country.
- Conditions
- Deglutition Disorders, Respiratory Distress Syndrome In Premature Infants, Respiratory Aspiration, Newborn, Premature
- Trial name
- NCT02661256
- Testing
- NCPAP, Varibar® Thin Liquid Barium Sulfate for Suspension
- Volunteers
- 7 people
- Sponsor
- NYU Langone Health
Neonatal, Premature Birth
Extending CPAP Therapy in Stable Preterm Infants to Increase Lung Growth and Function
This is a study to see if an extra 2 weeks of continuous positive airway pressure (CPAP) in stable preterm infants in the neonatal intensive care unit (NICU) can cause increased lung growth and lung function in the infants as…
- Conditions
- Neonatal, Premature Birth, Respiratory Distress Syndrome
- Trial name
- NCT04295564
- Testing
- Additional 2 weeks of CPAP
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Cynthia McEvoy
Acute Lung Injury, Acute Respiratory Distress Syndrome
Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
To evaluate whether administration of ganciclovir reduces serum IL-6 levels (i.e. reduction between baseline and 14 days post-randomization) in immunocompetent adults with severe sepsis or trauma associated respiratory failure.
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure
- Trial name
- GRAIL (NCT01335932)
- Testing
- IV Ganciclovir
- Where
- 14 sites in United States
- Volunteers
- 160 people
- Sponsor
- Fred Hutchinson Cancer Center
Acute Respiratory Distress Syndrome
LIPS-A: Lung Injury Prevention Study With Aspirin
The primary hypothesis was that early aspirin administration will decrease the rate of developing acute lung injury during the first 7 days after presentation to the hospital.
- Trial name
- NCT01504867
- Testing
- Aspirin, Lactose powder
- Where
- 16 sites in United States
- Volunteers
- 400 people
- Sponsor
- Mayo Clinic
Acute Respiratory Distress Syndrome
Human Mesenchymal Stem Cells For Acute Respiratory Distress Syndrome
This is a Phase 1, open label, dose escalation, multi-center clinical trial of Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells (hMSCs) for the treatment of Acute Respiratory Distress Syndrome (ARDS).
- Trial name
- START (NCT01775774)
- Testing
- Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Michael A. Matthay
Respiratory Distress Syndrome
Trial to Assess the Safety and Tolerability of Lucinactant for Inhalation in Premature Neonates
The primary objective of this study is to evaluate the safety and tolerability of aerosolized surfactant, specifically lucinactant for inhalation, administered in escalating inhaled doses to preterm neonates 29 to 34 weeks…
- Trial name
- NCT02074059
- Testing
- Lucinactant for Inhalation, nCPAP alone
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Windtree Therapeutics
Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome
The Budesonide in Babies (BiB) Trial
This is a Phase 3, randomized, masked, active-controlled, multicenter trial designed to determine whether early intratracheal administration of a combination of budesonide with surfactant, as compared to surfactant alone, will…
- Conditions
- Bronchopulmonary Dysplasia (BPD), Respiratory Distress Syndrome, Prematurity; Extreme, Neonatal
- Trial name
- BiB (NCT04545866)
- Testing
- budesonide (Pulmicort nebulizing suspension)., surfactant (poractant alfa;Curosurf)
- Where
- 19 sites in United States
- Volunteers
- 642 people
- Sponsor
- NICHD Neonatal Research Network
Respiratory Distress Syndrome
Cord Blood 25(oh)-Vitamin D Level in Preterm Infants and Associated Morbidities
Experimental and observational studies have shown that vitamin D deficiency may be associated with an increased risk for non-bone diseases and/or abnormal development for the other systems of fetus.
- Trial name
- NCT01812681
- Where
- Turkey (Türkiye)
- Volunteers
- 81 people
- Sponsor
- Dr. Sami Ulus Children's Hospital
Acute Respiratory Distress Syndrome
A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19
This is a study in adults with severe breathing problems because of COVID-19. People who are in hospital on breathing support can participate in the study.
- Trial name
- TRISTARDS (NCT04640194)
- Testing
- Standard of care, Alteplase low dose, Alteplase high dose
- Where
- 37 sites in Austria, Belgium and 11 more
- Volunteers
- 104 people
- Sponsor
- Boehringer Ingelheim
Acute Respiratory Distress Syndrome (ARDS)
LIPS-B: Lung Injury Prevention Study With Budesonide and Beta
This study tested whether inhaled budesonide and formoterol were able to alleviate or prevent pulmonary injury when administered early in hospital course to the patients at risk for developing acute respiratory distress syndrome…
- Trial name
- LIPS-B (NCT01783821)
- Testing
- Budesonide, Formoterol
- Where
- 5 sites in United States
- Volunteers
- 61 people
- Sponsor
- Mayo Clinic
SARS-CoV Infection
VERU-111 in the Treatment of SARS-Cov-2 Infection by Assessing Its Effect on the Proportion of Patients Who Die on Study
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of patients who die on study (prior to Day 60).
- Trial name
- VERU-111 (NCT04842747)
- Testing
- VERU-111
- Where
- 58 sites in United States, Argentina and 4 more
- Volunteers
- 204 people
- Sponsor
- Veru Inc.
Respiratory Distress Syndrome
Comparison of Curosurf and Infasurf in the Treatment of Preterm Infants With Respiratory Distress Syndrome
Premature infants frequently have trouble breathing after birth. If the respiratory disorder is caused by surfactant deficiency or dysfunction, the disease is treated with a medication called surfactant that is given to the…
- Trial name
- NEOSURF (NCT02834624)
- Testing
- Poractant alfa, calfactant
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Missouri-Columbia
COVID, Covid-19
A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19
The purpose of this study is to evaluate the safety and effectiveness of APL-9 in adults with mild to moderate ARDS (acute respiratory distress syndrome) caused by COVID-19 who are hospitalized and require supplemental oxygen…
- Conditions
- COVID, Covid-19, Coronavirus, Coronavirus Infection
- Trial name
- NCT04402060
- Testing
- APL-9, Vehicle Control
- Where
- 24 sites in United States, Brazil
- Volunteers
- 72 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
Bronchopulmonary Dysplasia (BPD) is a multi-factorial disease process that is the end result of an immature, surfactant deficient lung that has been exposed to hyperoxia, mechanical ventilation and infection.
- Trial name
- NCT01941745
- Testing
- Half normal saline, Low Dose rhCC10, High dose rhCC10
- Where
- 3 sites in United States
- Volunteers
- 88 people
- Sponsor
- Tufts Medical Center
Respiratory Distress Syndrome, Newborn
Delivery Room Management Trial of Premature Infants at High Risk of Respiratory Distress Syndrome
The best mode of delivery room stabilization for premature infants at high risk for respiratory distress syndrome is unknown. The protocol evaluates the impact of three distinct methods of post-delivery stabilization and…
- Trial name
- NCT00244101
- Testing
- PS Group, NCPAP Group, ISX Group
- Where
- United States
- Volunteers
- 648 people
- Sponsor
- Vermont Oxford Network
COVID, Sars-CoV2
Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)
This clinical trial will enroll participants that have pneumonia caused by the COVID-19 virus. During the study patients will receive 7 to up to 14 days of defibrotide.
- Conditions
- COVID, Sars-CoV2, COVID-19, Acute Respiratory Distress Syndrome
- Trial name
- NCT04530604
- Testing
- Defibrotide
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Gregory Yanik
Acute Lung Injury, Acute Respiratory Distress Syndrome
Airway Pressure Release Ventilation in Acute Lung Injury
The purpose of this study is to compare airway pressure release ventilation (APRV) to conventional mechanical ventilation (MV) in patients with acute lung injury (ALI) to determine if APRV can reduce agitation, delirium, and…
- Conditions
- Acute Lung Injury, Acute Respiratory Distress Syndrome, Mechanical Ventilation
- Trial name
- NCT00750204
- Testing
- APRV, Conventional MV
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Johns Hopkins University
Acute Respiratory Distress Syndrome, SARS-CoV-2
Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19
Evaluation of the safety, tolerability, and pharmacokinetics of PLN-74809 in participants with acute respiratory distress syndrome (ARDS) associated with at least severe COVID-19
- Trial name
- NCT04565249
- Testing
- PLN-74809
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Pliant Therapeutics, Inc.